Literature DB >> 7104811

Neostigmine reversal of D-tubocurarine and pancuronium bromide combinations in man.

D Z Frankel.   

Abstract

This study measured the neostigmine reversal of a non-depolarizing block in 17 patients, each given d-tubocurarine and pancuronium bromide in an alternating sequence. Reversal times were similar to those previously reported for pancuronium bromide alone. It is concluded that the anaesthetist may alternate between d-tubocurarine and pancuronium bromide without fear of difficulty with neostigmine reversal.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7104811     DOI: 10.1007/BF03007534

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  7 in total

1.  Train-of-4 quantitation of competitive neuromuscular block.

Authors:  C M Lee
Journal:  Anesth Analg       Date:  1975 Sep-Oct       Impact factor: 5.108

2.  Clinical neuromuscular pharmacology of pancuronium.

Authors:  R L Katz
Journal:  Anesthesiology       Date:  1971-06       Impact factor: 7.892

3.  The clinical pharmacology of metocurine: dimethyltubocurarine revisited.

Authors:  J J Savarese; H H Ali; R P Antonio
Journal:  Anesthesiology       Date:  1977-09       Impact factor: 7.892

4.  Variability in assessment of neuromuscular blockade.

Authors:  P Stiffel; S R Hameroff; C D Blitt; R C Cork
Journal:  Anesthesiology       Date:  1980-05       Impact factor: 7.892

5.  Potentiation of neuromuscular blockade in man produced by combinations of pancuronium and metocurine or pancuronium and d-tubocurarine.

Authors:  P W Lebowitz; F M Ramsey; J J Savarese; H H Ali
Journal:  Anesth Analg       Date:  1980-08       Impact factor: 5.108

6.  A new method for measuring PCO2 during anaesthesia.

Authors:  D Z Frankel; G Sandham; A S Rebuck
Journal:  Br J Anaesth       Date:  1979-03       Impact factor: 9.166

7.  Relative potency of ORG NC 45, pancuronium, alcuronium and tubocurarine in anaesthetized man.

Authors:  N Krieg; J F Crul; L H Booij
Journal:  Br J Anaesth       Date:  1980-08       Impact factor: 9.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.